Heron Therapeutics, Inc. (HRTX) has a consensus analyst rating of Buy, based on 19 analysts covering the stock. Of those, 19 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for HRTX is $6.67, representing a +597.2% upside from the current price of $0.9567. Price targets range from a low of $5.00 to a high of $9.00.
